Want to see JP:4263 full AI Analyst Report?
Top Page
SUSMED,Inc.
(4263)
Select Model
Select Model
Rating:44Neutral
Price Target:
¥456.00
▼(-44.46% Downside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial quality (large losses and persistent cash burn) despite strong revenue growth and very high gross margins. Technicals add further pressure, with the stock trading well below key moving averages and negative MACD indicating a strong downtrend. Valuation provides limited support because the company is unprofitable (negative P/E) and no dividend yield is available.
Positive Factors
Strong Revenue Growth
The sharp latest-year revenue increase indicates improving commercial traction and a growing business base. If sustained, continued top-line expansion could provide operating leverage and help the company absorb its currently heavy cost structure.
Negative Factors
Persistent Operating Losses
Large operating and net losses show that the current revenue base does not yet support the company’s cost structure. Widening losses could delay the path to self-sustaining profitability and increase reliance on the equity base or future funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
The sharp latest-year revenue increase indicates improving commercial traction and a growing business base. If sustained, continued top-line expansion could provide operating leverage and help the company absorb its currently heavy cost structure.
Read all positive factors
SUSMED,Inc. (4263) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.93B
Dividend YieldN/A
Average Volume (3M)121.17K
Price to Earnings (P/E)―
Beta (1Y)0.82
Revenue Growth7.39%
EPS Growth-27.75%
CountryJP
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-28.81
Shares Outstanding16,868,100
10 Day Avg. Volume117,240
30 Day Avg. Volume121,170
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)3.59
Price to Sales (P/S)29.38
P/FCF Ratio-26.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)46.6
Revenue Forecast (FY)¥2.20B
SUSMED,Inc. Business Overview & Revenue Model
Company Description
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, bre...
How the Company Makes Money
Publicly available, source-verifiable detail sufficient to describe SUSMED,Inc. (4263)’s specific revenue model (e.g., named business segments, primary product/service lines, pricing approach, or disclosed major partnerships) is not available in t...
SUSMED,Inc. Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
74
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 275.25M | 497.21M | 462.99M | 342.58M | 530.65M | 316.87M |
| Gross Profit | 260.05M | 479.82M | 450.72M | 330.85M | 522.67M | 306.50M |
| EBITDA | -475.95M | -319.99M | -289.22M | -350.22M | -43.99M | -231.11M |
| Net Income | -485.10M | -382.69M | -298.40M | -357.42M | -50.75M | -233.48M |
Balance Sheet | ||||||
| Total Assets | 4.22B | 4.22B | 4.50B | 4.93B | 5.10B | 4.94B |
| Cash, Cash Equivalents and Short-Term Investments | 3.96B | 3.70B | 4.40B | 4.85B | 5.05B | 4.90B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 114.37M | 147.94M | 132.33M | 327.79M | 230.33M | 93.34M |
| Stockholders Equity | 4.11B | 4.07B | 4.37B | 4.60B | 4.87B | 4.85B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -548.50M | -436.79M | -240.04M | 82.40M | -177.90M |
| Operating Cash Flow | 0.00 | -474.45M | -432.48M | -230.76M | 100.59M | -165.28M |
| Investing Cash Flow | 0.00 | -228.13M | -19.97M | -8.53M | -18.19M | -20.36M |
| Financing Cash Flow | 0.00 | 2.75M | 3.67M | 37.37M | 62.36M | 3.46B |
SUSMED,Inc. Technical Analysis
Negative
821.00
Price Trends
700.78
Negative
773.00
Negative
858.45
Negative
Market Momentum
-48.05
Positive
25.49
Positive
53.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4263, the sentiment is Negative. The current price of 821 is above the 20-day moving average (MA) of 601.90, above the 50-day MA of 700.78, and below the 200-day MA of 858.45, indicating a bearish trend. The MACD of -48.05 indicates Positive momentum. The RSI at 25.49 is Positive, neither overbought nor oversold. The STOCH value of 53.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4263.
SUSMED,Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥1.21T | 27.01 | 12.38% | 1.16% | 15.76% | 13.53% | |
71 Outperform | ¥224.48B | 33.04 | ― | 0.43% | 18.89% | 11.66% | |
59 Neutral | ¥87.96B | 45.14 | 6.35% | ― | 24.03% | 34.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | ¥7.93B | -19.99 | ― | ― | 7.39% | -27.75% | |
43 Neutral | ¥2.17B | -4.08 | ― | ― | 14.84% | 30.67% |
* Healthcare Sector Average
JP:4263
SUSMED,Inc.
454.00
-383.00
-45.76%
JP:2413
M3
1,855.00
-302.26
-14.01%
JP:4480
Medley
2,714.00
232.00
9.35%
JP:4438
Welby Inc.
255.00
-79.00
-23.65%
JP:4483
JMDC Inc.
3,500.00
-641.85
-15.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.